Kornimate/medical-research-clean huggingface dataset:
efficacy of reinforcing standard therapy in covid-19 patients with repeated transfusion of convalescent plasma

Conditions: Covid19

Summary: the coronavirus disease 2019 (covid-19) was classified as a pandemic by the world health organization (who) in march 2020. the sars-cov-2 virus is easily transmissible and there is currently no approved treatment with effective results. although the main epidemiological parameters are currently being studied, apparently the speed of contagion, the incidence and the mortality rate in severe cases appear to be high. therefore, there is an urgent need to find a viable therapeutic option. the present trial is a pilot study with an objective to determine the efficacy of standard treatment reinforced with two repeated doses in two consecutive days of plasma from former convalescent people of the covid-19 disease already discharged and / or with results in negative covid-19 screenings, transfused to hospitalized covid-19 patients.


Eligibility criteria:
inclusion criteria: * ability to understand the hip and sign the study ic * male or female =/\> 18 years * patient hospitalized with a covid-19 diagnosis by pcr on nasopharyngeal swabs or any other biological sample. * presence of respiratory symptoms and / or fever associated with covid-19, with clinical evolution time for covid-19 equal to or less than 7 days. * presence of pneumonia on chest x-ray and / or sato2 \<94% aa. * sequential organ failure assessment (sofa) score ≤ 6. * accept the condition of complying with the procedures established in the protocol. exclusion criteria: * patients with a previous history of allergic transfusion reaction. * lactating or pregnant women and a positive pregnancy test. * patients who have been treated with plasma in the 21 days prior to the screening / baseline visit. * patients who are at the time of study, participating in another clinical trial. * patients who haven't completed all study procedures.

Keywords: covid19, immune plasma
losartan therapy in pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: in addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (aceis) and angiotensin receptor blockers (arbs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. these beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. however, data regarding the use of aceis or arbs in the treatment of pht are limited. in this study, efficacy of an arb, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6mwt), cardiopulmonary exercise test, and endothelin-1 levels.losartan is as effective as nifedipine for reducing doppler echocardiographically measured pap and improving exercise capacity on 6mwt and cpet. however the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with pht.


Eligibility criteria:
inclusion criteria: * pulmonary hypertension diagnosed by doppler echocardiographic examination (a mean pulmonary artery pressure of \> 26mmhg) exclusion criteria: * acute infectious or inflammatory disease, * exacerbation of chronic obstructive pulmonary disease, * malignancy, * acute coronary syndrome in the last 4 weeks, * uncontrolled arrhythmia and hypertension, * decompensated heart failure, * acute pulmonary emboli, * thrombus in a lower extremity, * oxygen saturation below 85% at rest, * failure to cooperate with cpet

Keywords: pulmonary hypertension angiotensin receptor blocker calcium channel blocker
hand disability in systemic sclerosis - digital ulcers

Conditions: Systemic Sclerosis (SSc); Digital Ulcer

Summary: the aim of this study was to examine the turkish validity and reliability of the hand disability in systemic sclerosis - digital ulcers questionnaire (hdiss-du) in individuals with systemic sclerosis.


Eligibility criteria:
inclusion criteria: * diagnosed with ssc by a rheumatologist * being 18 years of age or older exclusion criteria: * presence of neurological disease * presence of any orthopedic problem that would affect functionality * presence of a history of orthopedic surgery * inability to speak or understand turkish fluently * presence of a psychiatric disease that would affect cooperation * severe neurological disease that would affect hand functions (peripheral nerve lesion, trauma, operation, cerebrovascular accident) * heart failure and lung pathology that would affect daily living activities
photoacoustic imaging of the breast in patients with breast cancer and healthy subjects

Conditions: Breast Carcinoma; Healthy Subject

Summary: this trial studies photoacoustic imaging of the breast in patients with breast cancer and healthy subjects. dense breasts typically reduce the sensitivity of a mammography and also is associated with a higher risk of breast cancer. photoacoustic tomography combines light and sound to provide more information about breast tissue.

primary objectives: i. to identify photoacoustic features of breast malignancy and treatment response outline: participants undergo photoacoustic imaging of the breast over 30 minutes. at subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.

Eligibility criteria:
inclusion criteria: * women with clinically suspicious or confirmed breast cancer masses (that have not been surgically removed) and will/have already undergo/undergone breast magnetic resonance imaging (mri). exclusion criteria: * pregnant women (there are no known risks to these procedures, but any unforeseen risks are as yet undetermined, so pregnant women will be excluded by means of a verbal confirmation at time of screening). * women who have had breast implants in the previous 6 months. * women who have had lumpectomy * adults unable to consent. * individuals who are not yet adults (infants, children, teenagers). * pregnant women. * prisoners. * there is no direct benefit of the study to any subject either non-english or english speaker. to facilitate the consent process, we will exclude non-english speaking subjects.
detection of acetylsalicylic acid and omega-3 fatty acids in schirmers' test strips using mass spectrometry

Conditions: Dry Eye

Summary: evaluation of tear fluid production using schirmers' tests is a well-known and frequently used examination method in ophthalmology. schirmers' test objectively indicates the tear fluid production over five minutes by insertion of a filter paper strip in the lower conjunctival fornix. commonly, this method is used to quantify tear fluid production, but not tear fluid composition. the development of novel, very precise analytical methods opens up new possibilities in the use and application of schirmers' test strips. a recently introduced analytical method is mass spectrometry. this method allows the detection and quantification of proteins, lipids, and metabolites in very low amounts of samples. whether systemically ingested agents such as omega-3 fatty acids or acetylsalicylic acid can be detected in tear fluid using this method remains unclear. the aim of this study is to investigate the detectability of 2 different agents (acetylsalicylic acid and omega-3 fatty acids) in schirmers' test strips from healthy subjects after intake for 1 week by use of untargeted mass spectrometry. participating healthy subjects will receive either acetylsalicylic acid or omega-3 fatty acids.


Eligibility criteria:
inclusion criteria: * men and women age of at least 18 years to 60 years * written informed consent prior to study-related procedures * normal ophthalmic findings * no use of eye drops including topical lubricants in the 4 weeks before screening exclusion criteria: * participation in a clinical trial in the 3 weeks preceding the study * symptoms of a clinically relevant illness in the 3 weeks before the first study day * presence or history of a severe medical condition as judged by the clinical investigator * intake of any drugs or dietary supplements within three weeks before the first study day (except contraceptives) * tfbut \<10 sec. * glaucoma in the medical history * ocular infection or clinically significant inflammation * ocular surgery in the 3 months preceding the study * pregnancy, planned pregnancy or lactating * known hypersensitivity to any component of the study medication
evaluating the effectiveness of osteopathy in the management of pain in elderly people

Conditions: Osteopathy

Summary: this type of study can have an impact on public health policy and help improve the management of pain in people with ehpad; propose better use of drug treatments and non-pharmacological methods such as osteopathy; help structuring the healthcare sector.

* "osteopathy" group: 3 osteopathy sessions of 45 min with one session every 3 weeks at s2, s5 and s8. fascial osteopathic techniques performed will consist of gentle and non-impulsive manipulation * "simulated" group: 3 simulated osteopathy sessions lasting 45 minutes, one session every 3 weeks at s2, s5 and s8. the techniques performed will consist of an application of the hands to different anatomical regions than the group "osteopathy" without therapeutic intention, that is to say without tissue tensioning. the pain will be assessed at inclusion (s0) and at the end of the procedure (s12) by the head physician, the coordinating physician or the psychomotor therapist, ignoring the assignment group of the subject and before each session. osteopathy (at s2, s5 and s8) by a nurse or psychomotor also ignoring the patient's assignment group. both groups will continue to benefit from their usual allopathic management and recommendations. patients will not be aware of the treatment received (osteopathy or simulated) and will be randomized by a computer server.

Eligibility criteria:
inclusion criteria: * patients older than 75 years * patients residing in accommodation facilities for dependent old people * a score measured by the doloplus 2 scale at least 7/30 at the start of the study * for patients in capacity and autonomous: patients informed and having signed a free and informed consent. for non-capable patients with a trusted person and / or guardian: informed patients whose confidant or guardian has been informed and has signed free and informed consent. - affiliated to a social security scheme (beneficiary or beneficiary) exclusion criteria: * absence of pain * medical contraindication known to the practice of osteopathy with fascial aim (advanced degenerative bone disease, metastatic cancer) * osteopathic treatment in the last six months * patients under curators
study evaluating cemiplimab alone and combined with rp1 in treating advanced squamous skin cancer

Conditions: Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma

Summary: to estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with rp1 for patients with locally advanced or metastatic cscc, as assessed by overall response rate (orr) and complete response rate (crr) according to blinded independent review.

rp1 is a selectively replication competent herpes simplex virus type 1(hsv-1). this is a phase 1/2, open-label, multicenter repeat-dosing study of rp1 alone and in combination with nivolumab in patients with advanced malignancies, and contains both single agent dose escalation, dose expansion to include nivolumab, and the combination in multiple phase 2 cohorts in individual tumor types.

Eligibility criteria:
key inclusion criteria: * histologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma * patients with locally advanced disease who are not suitable candidates for surgical or radiological treatment of lesions or have refused those treatments * at least 1 lesion that is measurable and injectable by study criteria * eastern cooperative oncology group (ecog) performance status ≤1. patients with ecog ps 2 at baseline may be allowed to enroll if ps 2 status is only related to the cscc disease under study * anticipated life expectancy \>12 weeks * all patients must consent to provide archived or newly obtained tumor material for central pathology review for confirmation of diagnosis of cscc. key exclusion criteria: * prior treatment with an oncolytic therapy * patients with active significant herpetic infections or prior complications of hsv-1 infection (e.g. herpetic keratitis or encephalitis) * patients who require intermittent or chronic use of systemic (oral or intravenous) anti-virals with known anti-herpetic activity (e.g. acyclovir) * ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments * prior treatment with an agent that blocks the pd-1/pd-l1 pathway. * prior treatment with other immune modulating agents other than as adjuvant or neoadjuvant therapy within 3 years. * untreated brain metastasis(es) that may be considered active. * acute or chronic active hepatitis b or known history of hepatitis b or hepatitis c or human immunodeficiency virus (hiv) infection * history of ild/pneumonitis within the last 5 years or a history of ild/pneumonitis requiring treatment with systemic steroids. * any major or surgical procedure ≤ 28 days before randomization * administration of live vaccines ≤ 28 days before randomization note: other protocol defined inclusion/exclusion criteria apply.

Keywords: oncolytic virus carcinoma carcinoma, squamous cell cemiplimab metastatic cutaneous squamous cell carcinoma oncolytic immuno-gene therapy
mindfulness approach for reducing anxiety and gloom in ocular inflammatory diseases

Conditions: Non-infectious Uveitis

Summary: the proposed study is a block-randomized, controlled trial to evaluate the effects of a digital meditation and mindfulness practice on mental health in patients with non-infectious uveitis.

non-infectious uveitis is an immune-mediated inflammatory disease of the eye that can occur alone or be associated with other autoimmune diseases. this chronic condition can be isolating and complex for patients to manage, leading to increased rates of anxiety and depression symptoms in uveitis patients compared to the general population. in collaboration with calm health, the investigators aim to evaluate the efficacy of calm health's meditation, mindfulness, and clinical programs in reducing symptoms of anxiety and depression, as well as perceived stress, in patients. overall, the investigators aim to collect data on the value of supplementing medical care with an accessible digital mental health resource.

Eligibility criteria:
inclusion criteria: * is 18 or older at time of enrollment. * is willing to download calm health on their smartphone * is able to operate a smartphone \& calm health without assistance * is able to read words on a screen without assistance * diagnosis of non-infectious uveitis exclusion criteria: * is under 18 at time of enrollment. * has started taking a new anti-depressant, anti-anxiety, or other psychiatric medication to improve mood within the past month. * plans to start taking a new anti-depressant, anti-anxiety, or other psychiatric medication to improve mood in the next 12 weeks. * has started any type of psychotherapy within the past 3 months. * plans to start any type of psychotherapy within the next 12 weeks. * already has a mindfulness/meditation app on their smartphone. * is unable to operate a smartphone or read words on a screen without assistance. * is unable or unwilling to download the calm health app on their smartphone. * does not consent to their anonymized data being collected via calm health app.
urdu version of northwick park neck pain questionnaire: reliability and validity study

Conditions: Neck Pain

Summary: * to adapt culturally neck pain questionnaire in urdu language. * to check the reliability of urdu version of neck pain questionnaire * to validate neck pain questionnaire by neck disability index and visual analogue scale and numeric pain rating scale.

the original english version of northwick park neck pain questionnaire will be translated and culturally adapted as per previous recommendation. in patients with neck pain, urdu version of northwick park neck pain questionnaire will be distributed among 70 participants choose a convenience sampling technique based on pre-defined inclusion and exclusion criteria. to test reliability of inter/intra observer of ultimate final urdu version of northwick park neck pain questionnaire will be filled from patients on the equivalent day, by 2 different bystanders, and for inter observer valuation, with an interval of 30 minutes between the first and second application. third assessment will be carried out after 7 days of the observer -1, for intra-observer assessment. data will be entered and analyzed cronbach alpha value. test-retest reliability will be assessed using an intraclass correlation coefficient. urdu version of northwick park neck pain questionnaire will be evaluated for content validity, construct validity, criterion validity and responsiveness.

Eligibility criteria:
inclusion criteria: 1. both male and female 2. minimum age is 18 years 3. maximum age up to 60 years 4. people with chronic neck pain 5. duration of pain more then 3 months 6. no history of neck therapy 7. not had any neck therapy exclusion criteria: 1. people with medical history regarding skeleton issues 2. people with traumas 3. having neck surgery 4. people with neurological deficits ( like malignancies or inflammatory arthritis) 5. people went for therapy were also excluded. 6. people with age more than 60 and less than 18 were excluded..

Keywords: northwick park neck pain questionnaire urdu version reliability validity neck pain
real-world evidence of effectiveness and safety of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma in taiwan: a nationwide study

Conditions: Primary Central Nervous System Lymphoma (PCNSL)

Summary: the goal of this observational study is to describe the real-world effectiveness and safety of tirabrutinib among relapsed or refractory pcnsl patients in taiwan.


Eligibility criteria:
inclusion criteria: 1. patient is ≥ 18 years of age. 2. r/r pcnsl patient, who has newly started nhi public reimbursement tirabrutinib from 01 june 2024 to 30 june 2025. 3. have provided voluntary written consent, directly from the subject, or through his/her legal representative for a patient who has died or lacks the capacity to give informed consent note: the nhi reimbursement criteria are listed below for reference purposes only. subject enrollment depends on whether reimbursement has been received. 1. histopathologically confirmed large b-cell pcnsl. 2. patients with relapsed or refractory pcnsl previously treated at least 2 cycles of hd-mtx. 3. exclude hiv infection 4. exclude burkitt lymphoma 5. exclude patients using chemotherapy or monoclonal antibodies at the initiation of tirabrutinib treatment.
pik3ca mutational status assessment

Conditions: Breast Cancer Metastatic

Summary: evaluation of pik3ca mutational status: a route towards a tailored diagnostic approach.

evaluate the effectiveness and concordance of molecular methods in identifying mutations affecting the pik3ca gene both on paraffin tissue sections of the tumor and on liquid biopsy of patients with breast cancer treated at the ieo. the molecular test on the liquid biopsy of same patient could bring an important benefit considering that the withdrawal of this biomaterial turns out to be less invasive than a biopsy performed on an organ

Eligibility criteria:
inclusion criteria: * • participant has a histologically and/or cytologically confirmed diagnosis of er+ and/or pgr+ breast cancer by local laboratory. * participant has her2-negative breast cancer defined as a negative in situ hybridization test or an ihc status of 0, 1+ or 2+. if ihc is 2+, a negative in situ hybridization (fluorescent in situ hybridization (fish), chromogenic in situ hybridization (cish), or silver-enhanced in situ hybridization (sish)) test is required by local laboratory testing. * participants should be at advanced or metastatic setting prior to treatment. * written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * patients must be accessible for follow-up. exclusion criteria: patients already treated with different treatments like chemotherapy, hormone therapy etc -
a phase i/ii study of itu512 in healthy participants and patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (pk), and preliminary food effect of itu512 as well as the fetal hemoglobin (hbf)-inducing capacity of itu512. this will be the first evaluation of the potential therapeutic effect of itu512 in healthy participants and patients with sickle cell disease (scd).

this is a global, randomized, phase i/ii study to assess the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and preliminary food effect of single-agent itu512 in adult healthy participants, and safety, tolerability, pk, pd, and efficacy of itu512 in adolescent and adult patients with sickle cell disease (scd). the study consists of a first-in-human phase i study (part 1) in healthy participants, and a phase ii study (part 2) in patients with scd. part 1 will comprise of part 1a, part 1b, and part 1c. part 2 may include an extension part.

Eligibility criteria:
key inclusion criteria: part 1 (healthy participants) * healthy male participants and female participants of non-childbearing potential between 18-55 years of age * in good health as determined by the investigator's assessment of medical history, physical examination, vital signs, ecg, and laboratory tests * participants must weigh at least 50 kg at screening and first baseline (admission) and must have a body mass index (bmi) within the range of 18.0-32.0 kg/m2 inclusive. part 2 (sickle cell disease) - male and female participants with a diagnosis of sickle cell disease key exclusion criteria: part 1 (healthy participants) * qtcf ≥ 450 msec (as a mean value of triplicates) * history of arrhythmias * history of significant illness which has not resolved within two (2) weeks prior to initial dosing * women of child-bearing potential (wocbp) part 2 (sickle cell disease) * current use of hydroxyurea/hydroxycarbamide (hu/hc) * qtcf ≥ 450 msec (as a mean value of triplicates) * history of arrhythmias other protocol-defined inclusion/exclusion criteria may apply.

Keywords: itu512 low molecular weight small molecule sickle cell disease